Class IA PI3Ks (phosphoinositide 3-kinases) regulate a wide range of cellular responses through the production of PI(3,4,5)P 3 (phosphatidylinositol 3,4,5-trisphosphate) in cellular membranes. They are activated by receptor tyrosine kinases, by Ras and Rho family GTPases, and in some cases by G βγ subunits from trimeric G-proteins. Crystallographic studies on the related class IB PI3Kγ , and biochemical and structural studies on the class IA PI3Ks, have led to new insights into how these critical enzymes are regulated in normal cells and how mutations can lead to their constitutive activation in transformed cells. The present paper will discuss recent studies on the regulation of class I (p85/p110) PI3Ks, with a focus on the role of SH2 domains (Src homology 2 domains) in the p85 regulatory subunit in modulating PI3K activity.
Regulation of class IA PI3Ks (phosphoinositide 3-kinases)
PI3Ks are critical regulators of proliferation, motility, apoptosis and vesicular trafficking [1, 2] . Mammalian cells express multiple PI3Ks that are regulated by different mechanisms and produce different 3-phosphoinositide products. The best characterized, the class I PI3Ks, are heterodimers composed of separate regulatory and catalytic subunits. They produce primarily PI(3,4,5)P 3 (phosphatidylinositol 3,4,5-trisphosphate) in vivo [1] [2] [3] . Class IA enzymes are activated by receptor tyrosine kinases and Rho family GTPases, whereas class IB enzymes (PI3Kγ ) are activated by heterotrimeric G-proteins [4] [5] [6] [7] . Both can be activated by p21-ras [8, 9] . Multiple isoforms have been described for the class IA regulatory subunit (p85α, p85β, p55α, p50α and p55γ ) and catalytic subunit (p110α, p110β and p110δ) [1, 2] . They are ubiquitous with the exception of p110δ (expressed in leucocytes [10] ). Mutations in the p110α class IA catalytic subunit are found at high frequencies in human cancer, suggesting that PI3Ks are clinically significant oncogenes [11, 12] .
Domain organization of class IA PI3Ks p85 regulatory subunit
The class IA p85 regulatory subunit contains modular domains that mediate interactions with other signalling proteins (Figure 1 ). p85 contains a single SH3 domain (Src homology 3 domain) and two proline-rich domains. The SH3 domain binds to a number of proteins in vitro [13] , but its physiological targets are unclear. The BCR (Breakpoint Cluster Region) homology domain is homologous with a domain of the BCR gene product [14] . It binds to Rac and Cdc42 (cell division cycle 42) [6, 7] , and has GAP (GTPase-activating protein) activity towards the Rab GTPases [15] . Finally, p85 contains two SH2 domains that bind with high affinity to phosphorylated (P)YXXM motifs [16] . The region between the two SH2 domains, the iSH2 (inter-SH2) domain, binds to the N-terminal domain [ABD (adaptor-binding domain)] of p110α, p110β or p110γ [17] [18] [19] . We used site-directed spin labelling and EPR spectroscopy to show that the iSH2 domain is a 100 Å -long rigid coiled coil (1 Å = 0.1 nm) [20] .
p110 catalytic subunit
The crystal structure of the PI3Kγ catalytic subunit [21] suggests a modular organization for p110 ( Figure 1 ). The p110 ABD is sufficient for binding to the p85 iSH2 domain [17] [18] [19] 22] . A Ras-binding domain binds to activated Ras, which increases p85/p110 activity [8] . A C2 domain, similar to that found in phospholipase Cδ1 [21] , is followed by a helical domain. Finally, the C-terminus of p110 contains a two-lobed kinase domain similar to that found in protein kinases [23] . Although p110 has serine/threonine protein kinase activity and phosphorylates itself and p85 [24, 25] , few in vivo substrates have been identified [24, [26] [27] [28] [29] .
Regulation class IA PI3Ks p85 inhibits p110, and activation of p85-p110 dimers reflects disinhibition of p110 [30] [31] [32] . Although the iSH2 domain of p85 is sufficient to bind p110 [17] [18] [19] 22] , inhibition of p110 by p85 additionally requires the N-terminal SH2 domain linked to the iSH2 domain (p85ni) [33] . Isolated iSH2 (p85i) or iSH2-cSH2 (C-terminal SH2) (p85ic) fragments bind p110 but do not affect its activity. Isolated nSH2 (N-terminal SH2) domains neither bind nor inhibit p110.
p85-p110 dimers are activated when the p85 SH2 domains bind to proteins containing phosphorylated (P)YXXM motifs [34] [35] [36] . This regulation does not involve the dissociation of p85 from p110, as monomeric p110 is unstable at 37
• C The p85 regulatory subunit contains SH3, proline-rich (PRD), BCR and SH2 domains. The iSH2 domain of p85, a 100 Å-long rigid coiled coil, binds to the ABD of p110. The p110 catalytic subunit also contains Ras-binding, C2, helical and catalytic domains.
and is rapidly degraded unless dimerized with p85 [31] . This means that regulation must occur via a conformational change in p85 that is transmitted to p110. A recent study proposed that the iSH2 domain is a conformational switch [37] , based on the effects of overexpressed p85 fragments on the activation of Akt (also called protein kinase B) by oncogenic Ras, an indirect measure of PI3K activity. In fact, we have used EPR spectroscopy to show that the iSH2 domain undergoes minimal conformational change in response to phosphopeptide binding to the nSH2 domain, even when bound to the p110 ABD [20, 38] . These results were consistent with an earlier [ 19 F]NMR study, which also predicted a rigid iSH2 domain [39] . Thus the iSH2 domain is not a conformational switch.
In contrast, our results suggest that the nSH2 domain is a conformational switch. We have shown that the nSH2 domain adopts a preferred conformation with regard to the iSH2 domain, forming a close contact with residues 571-598 in the iSH2 domain [40] . Truncation of p85 at residue 572, which removes these residues, abolishes inhibition of p110, leading to a constitutively active PI3K [40] . Deletions and truncations in this region of p85 have been reported in human and murine cancer [41] [42] [43] . These results suggest that the orientation of the nSH2 relative to the iSH2 is critical for inhibition of p110. Based on these findings, we have proposed a model in which the p110 ABD binds to the rigid iSH2 domain (Figure 2 ) [40] . This positions p110 such that the p85 nSH2 domain can make a second, inhibitory contact with another region of p110. The nSH2 domain is maintained in this inhibitory orientation by its contacts with residues 571-598 of the iSH2 domain.
While the site of inhibitory interactions between p85 and p110 is not yet known, the identification of residues in p110α that are frequently mutated in human cancer [11] provides a clue. These mutations activate p110α and are sufficient to transform cultured cells [12] . Given our model of p85 inhibition of p110, we predict that some of these activating mutations might disrupt the inhibitory contact between p110 and the nSH2 domain. As suggested by Shekar et al. [40] , there may be mechanistic symmetry between oncogenic mutants of both p85 and p110. Maintenance of p110α activity in the basal state requires an inhibitory contact with the nSH2 domain of p85. The nSH2 domain is maintained in the correct inhibitory position by its contacts with the distal iSH2 domain [40] . Mutations that disrupt either the positioning of the nSH2 domain (e.g. truncations in the distal iSH2 domain) or its contact site in p110α (e.g. hot spot mutations in p110) would lead to a loss of inhibition, and constitutive and unregulated PI3K activity. Important avenues for future investigation include defining the putative inhibitory interface, determining how it is modulated by physiological activators such as tyrosine-phosphorylated proteins that bind to the nSH2 domain and activated GTPases that bind to the BCR homology domain of p85 [6, 7, 44] , and defining the mechanism by which phosphopeptide binding to the nSH2 domain facilitates subsequent activation by Ras-p110 interactions [45] . 
